查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1890971

按適應症、劑量、給藥途徑、分銷管道、年齡層、最終用戶和地區分類的磺達肝癸鈉市場

Fondaparinux Market, By Indication, By Dosage Strength, By Route of Administration, By Distribution Channel, By Age Group, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

據估計，2025 年磺達肝癸鈉市值為 7.355 億美元，預計到 2032 年將達到 11.354 億美元，2025 年至 2032 年的複合年成長率為 6.4%。

報告內容 報告詳情
基準年： 2024 2025年市場規模： 7.355億美元
歷史數據時期： 2020-2024 預測期： 2025-2032
預測期間（2025-2032年）： 6.40% 2032 年的預測值： 11.354億美元

全球磺達肝癸鈉市場在抗凝血劑產業中佔據重要地位，它主要是一種合成五糖藥物，用於預防和治療血栓性栓塞症。

磺達肝癸鈉（主要以Arixtra等商品名銷售）是一種選擇性Xa因子抑制劑，與傳統的肝素抗凝血劑相比，其藥理特性更優。這種合成化合物具有極佳的生物利用度、可預測的藥物動力學，且肝素誘導的血小板減少性疾病減少症風險較低，因此日益成為全球醫療保健機構的首選治療方案。

該市場涵蓋了多種臨床應用領域，例如預防深層靜脈栓塞症、治療肺動脈栓塞以及外科手術（尤其是整形外科手術）的手術全期手術期抗凝血管理。

心血管疾病盛行率上升、全球人口老化、外科手術數量增加以及人們對血栓性栓塞症併發症的認知不斷提高，正在推動市場顯著擴張。世界各地的醫療系統都認知到磺達肝癸鈉的臨床優勢，例如每日一次給藥的便利性、藥物相互作用少以及安全性高，這些優勢促使其在醫院和門診環境中得到廣泛應用，從而為市場的持續成長奠定了基礎。

市場動態

由於多種有利因素，全球磺達肝癸鈉市場正經歷強勁成長。主要促進因素是全球心血管疾病和血栓栓塞性疾病負擔日益加重，導致不同患者族群對有效抗凝血治療的需求不斷成長。全球人口老化也是市場成長的重要因素，因為老年患者發生靜脈血栓栓塞症的風險較高，因此需要預防和治療性介入。磺達肝癸鈉憑藉其卓越的療效和安全性，滿足了這項需求。

外科手術量不斷增加，尤其是包括髖關節和膝關節關節重建術在內的整形外科手術，對可靠的抗凝血通訊協定產生了巨大的需求，而磺達肝癸鈉因其可預測的藥物動力學和較低的監測要求而成為首選藥物。

然而，該藥物的市場成長受到諸多限制，主要原因是其高成本高於傳統抗凝血劑（如未分級肝素） ，這使得價格敏感的醫療市場難以負擔，也限制了其在資源匱乏地區的應用。此外，儘管其發生嚴重出血併發症的風險低於傳統抗凝血劑，但出血風險仍然是一個臨床問題，影響藥物的配發模式，並需要嚴格的患者篩選和監測通訊協定。

透過在癌症相關血栓症管理和門診抗凝血治療等新興治療領域拓展適應症，市場蘊藏著巨大的機會。磺達肝癸鈉憑藉著便利性和安全性優勢，展現出強大的競爭優勢。非專利藥進入各個區域市場，為提高藥物可近性和市場滲透率創造了機會，尤其是在開發中國家，成本因素對治療決策有顯著影響。同時，正在進行的探索新適應症和聯合治療的臨床研究有望開發新的收入來源，並擴大目標患者群體。

本次調查的主要特點

  • 本報告對全球磺達肝癸鈉市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和復合年成長率（%）。
  • 它還指出了每個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
  • 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業。
  • 該研究根據以下參數對全球磺達肝癸鈉市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
  • 本報告的研究結果將幫助負責人和經營團隊就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
  • 這份全球磺達肝癸鈉市場報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過全球磺達肝癸鈉市場分析中使用的各種策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

  • 調查目的
  • 先決條件
  • 簡稱

第2章 市場範圍

  • 報告概述
    • 市場定義和範圍
  • 執行摘要

第3章：市場動態、監理及趨勢分析

  • 市場動態
  • 促進要素
  • 抑制因素
  • 機會
  • 影響分析
  • 法規環境
  • 產品上市及核准
  • PEST分析
  • 波特分析
  • 併購趨勢
  • 產業趨勢

4. 2020-2032年全球磺達肝癸鈉市場依適應症分類

  • 靜脈血栓栓塞症(VTE) 預防
  • 深層靜脈栓塞症（DVT）治療
  • 肺動脈栓塞（PE）治療
  • 急性冠狀動脈症候群（ACS）

5. 2020-2032年全球磺達肝癸鈉市場（依劑量分類）

  • 2.5mg
  • 5mg
  • 7.5mg
  • 10mg

6. 2020-2032年全球磺達肝癸鈉市場依給藥途徑分類

  • 預填充式注射器
  • 管瓶

7. 2020-2032年全球磺達肝癸鈉市場依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

8. 2020-2032年全球磺達肝癸鈉市場依年齡層分類

  • 成人
  • 老年人
  • 兒童

9. 2020-2032年全球磺達肝癸鈉市場（依最終用戶分類）

  • 醫院
  • 專科診所
  • 門診手術中心
  • 專業心臟中心
  • 診斷中心
  • 居家醫療機構

10. 2020-2032年全球磺達肝癸鈉市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 北非
    • 中非

第11章 競爭格局

  • Sanofi
  • Viatris
  • Dr Reddy's Laboratories Ltd
  • Aurobindo Pharma Ltd
  • GlaxoSmithKline plc
  • Jiangsu Hengrui Medicine Co Ltd
  • Aspen API
  • BrightGene Bio-Medical Technology Co Ltd
  • Formosa Laboratories Inc
  • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
  • ScinoPharm Taiwan Ltd
  • Pfizer Inc
  • Eugia Pharma Specialities Ltd
  • Fresenius Kabi
  • Hikma Pharmaceuticals plc

第12章 分析師建議

  • 機會
  • 一致的機會地圖

第13章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI8953

Fondaparinux Market is estimated to be valued at USD 735.5 Mn in 2025 and is expected to reach USD 1,135.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 735.5 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.40% 2032 Value Projection: USD 1,135.4 Mn

The global fondaparinux market represents a critical segment within the anticoagulant pharmaceutical industry, focusing on synthetic pentasaccharide medications designed to prevent and treat thromboembolic disorders.

Fondaparinux, marketed primarily under brand names such as Arixtra, functions as a selective Factor Xa inhibitor, offering superior pharmacological properties compared to traditional heparin-based anticoagulants. This synthetic compound demonstrates exceptional bioavailability, predictable pharmacokinetics, and reduced risk of heparin-induced thrombocytopenia, making it an increasingly preferred therapeutic option for healthcare providers worldwide.

The market encompasses various clinical applications including deep vein thrombosis prevention, pulmonary embolism treatment, and perioperative anticoagulation management across surgical procedures, particularly orthopedic interventions.

Growing prevalence of cardiovascular diseases, aging global population demographics, increasing surgical procedures, and rising awareness regarding thromboembolic complications are driving substantial market expansion. Healthcare systems worldwide are recognizing fondaparinux's clinical advantages, including once-daily dosing convenience, minimal drug interactions, and enhanced safety profiles, contributing to its growing adoption in both hospital and outpatient settings, positioning this market for sustained growth trajectory.

Market Dynamics

The global fondaparinux market experiences robust growth driven by multiple compelling factors, with the primary driver being the escalating global burden of cardiovascular diseases and thromboembolic disorders, necessitating effective anticoagulation therapies across diverse patient populations. The aging demographic worldwide significantly contributes to market expansion, as elderly patients face heightened risks of venous thromboembolism, requiring prophylactic and therapeutic interventions where fondaparinux demonstrates superior efficacy and safety profiles.

Increasing surgical procedures, particularly orthopedic surgeries including hip and knee replacements, create substantial demand for reliable anticoagulation protocols, with fondaparinux emerging as the preferred choice due to its predictable pharmacokinetics and reduced monitoring requirements.

However, market growth faces significant restraints, primarily centered around the medication's high cost compared to traditional anticoagulants like unfractionated heparin, creating affordability challenges in price-sensitive healthcare markets and limiting adoption in resource-constrained settings. Additionally, the risk of major bleeding complications, though lower than conventional anticoagulants, remains a clinical concern that influences prescribing patterns and requires careful patient selection and monitoring protocols.

The market presents substantial opportunities through expanding applications in emerging therapeutic areas, including cancer-associated thrombosis management and outpatient anticoagulation programs, where fondaparinux's convenience and safety advantages offer competitive positioning. Generic formulations entering various regional markets create opportunities for increased accessibility and market penetration, particularly in developing economies where cost considerations significantly influence treatment decisions, while ongoing clinical research exploring novel indications and combination therapies promises to unlock additional revenue streams and expand the addressable patient population.

Key Features of the Study

  • This report provides in-depth analysis of the global fondaparinux market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fondaparinux market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, Viatris, Dr Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, GlaxoSmithKline plc, Jiangsu Hengrui Medicine Co Ltd, Aspen API, BrightGene Bio-Medical Technology Co Ltd, Formosa Laboratories Inc, Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd, ScinoPharm Taiwan Ltd, Pfizer Inc, Eugia Pharma Specialities Ltd, Fresenius Kabi, and Hikma Pharmaceuticals plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global fondaparinux market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fondaparinux market

Market Segmentation

  • Indication Insights (Revenue, USD Mn, 2020 - 2032)
    • Venous Thromboembolism (VTE) Prophylaxis
    • Deep Vein Thrombosis (DVT) Treatment
    • Pulmonary Embolism (PE) Treatment
    • Acute Coronary Syndrome (ACS)
  • Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
    • 2.5 mg
    • 5 mg
    • 7.5 mg
    • 10 mg
  • Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
    • Pre-filled Syringes
    • Vials
  • Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Age Group Insights (Revenue, USD Mn, 2020 - 2032)
    • Adult
    • Geriatric
    • Pediatric
  • End User Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Specialty Cardiac Centers
    • Diagnostic Centers
    • Homecare Settings
  • Regional Insights (Revenue, USD Mn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Sanofi
    • Viatris
    • Dr Reddy's Laboratories Ltd
    • Aurobindo Pharma Ltd
    • GlaxoSmithKline plc
    • Jiangsu Hengrui Medicine Co Ltd
    • Aspen API
    • BrightGene Bio-Medical Technology Co Ltd
    • Formosa Laboratories Inc
    • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
    • ScinoPharm Taiwan Ltd
    • Pfizer Inc
    • Eugia Pharma Specialities Ltd
    • Fresenius Kabi
    • Hikma Pharmaceuticals plc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Fondaparinux Market, By Indication
    • Global Fondaparinux Market, By Dosage Strength
    • Global Fondaparinux Market, By Route of Administration
    • Global Fondaparinux Market, By Distribution Channel
    • Global Fondaparinux Market, By Age Group
    • Global Fondaparinux Market, By End User
    • Global Fondaparinux Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Fondaparinux Market, By Indication, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Venous Thromboembolism (VTE) Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Deep Vein Thrombosis (DVT) Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Pulmonary Embolism (PE) Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Acute Coronary Syndrome (ACS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Fondaparinux Market, By Dosage Strength, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • 2.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 7.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Fondaparinux Market, By Route of Administration, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pre-filled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Fondaparinux Market, By Distribution Channel, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Fondaparinux Market, By Age Group, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Fondaparinux Market, By End User, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Specialty Cardiac Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Fondaparinux Market, By Region, 2020 - 2032, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr Reddy's Laboratories Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aurobindo Pharma Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Jiangsu Hengrui Medicine Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aspen API
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BrightGene Bio-Medical Technology Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Formosa Laboratories Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ScinoPharm Taiwan Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eugia Pharma Specialities Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fresenius Kabi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About us